Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops

Biocontrol Science

Volumn 17, Issue 3, 2012, Pages 121-128

  Ayaki, Masahiko ^a   Iwasawa, Atsuo ^b   Niwano, Yoshimi ^c  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Benzalkonium chloride; Cell viability score; Eye drops; Glaucoma; Toxicity

Indexed keywords

BENZALKONIUM; BENZALKONIUM CHLORIDE; CELL VIABILITY; DORZOLAMIDE; EYE DROPS; GLAUCOMA; IN-VITRO; NEUTRAL RED; TEST SOLUTIONS; TIMOLOL;

CELL CULTURE; CHLORINE COMPOUNDS; TOXICITY;

CYTOTOXICITY;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BIMATOPROST; BRIMONIDINE PLUS TIMOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST PLUS TIMOLOL; TAFLUPROST; TIMOLOL PLUS TRAVOPROST;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GLAUCOMA; HUMAN; HUMAN CELL; NONHUMAN;

ANIMALS; BENZALKONIUM COMPOUNDS; CATTLE; CELL LINE; CELL SURVIVAL; DRUG COMBINATIONS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; RABBITS; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 84867671953     PISSN: 13424815     EISSN: 18840205     Source Type: Journal    
DOI: 10.4265/bio.17.121     Document Type: Article

References (29)

1. Ammar, D. A., Noecker, R. J., and Kahook, M.Y. (2011) Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv. Ther., 28, 501-510.
2. Asada, H., Takaoka-Shichijo, Y., Nakamura, M., and Kimura, A. (2010) Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy. Yakugaku Zasshi, 130, 867-871. in Japanese.
3. Ayaki, M., and Iwasawa, A. (2010). Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin. Ophthalmol., 4, 919-924.
4. Ayaki, M., Iwasawa, A., and Niwano, Y. (2011a) Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cells. Jpn. J. Ophthalmol., 55, 541-546.
5. Ayaki, M., and Iwasawa, A. (2011b) Critical concentration of benzalkonium chloride in eye drop for toxicity in cultured ocular surface cell lines. Inv. Ophthalmol. Vis. Sci., 52, E-Abstract 1955.
6. Ayaki, M, Yaguchi, S, Iwasawa, A, and Koide, R. (2011c) Cytotoxicity of six ophthalmic solutions containing carteolol for four cultured corneal and conjunctival cell lines. Folia Japonica de Ophthalmologica Clinica. (in Japanese), 4, 348-354.
7. Baudouin, C., Labbé, A., Liang, H., Pauly, A., and Brignole-Baudouin, F. (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res., 29, 312-334.
8. Boyle, J.E., Ghosh, K., Gieser, D.K., and Adamsons, I.A. (1998) A randomized trial comparing the dorzolamide/timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology, 105, 1945-1951.
9. Brasnu, E., Brignole-Baudouin, F., and Riancho, L. (2008) In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye Res., 33, 303-312. (Pubitemid 351507760)
10. Craven, E. R., Walters, T. R., Williams, R., Chou, C., Cheetham, J. K., and Schiffman, R.; Combigan Study Group. (2005) Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther., 21, 337-348. (Pubitemid 41192905)
11. Feghhi, M., Mahmoudabadi, A. Z., and Mehdinejad, M. I. (2008) Evaluation of fungal and bacterial contaminations of patient-used ocular drops. Med. Mycol., 46, 17-21. (Pubitemid 351298236)
12. Fudemberg, S.J., Batiste, C., and Katz, L. J. (2008) Efficacy, safety, and current applications of brimonidine. Expert Opin. Drug Saf., 7, 795-799. Review.
13. Furrer, P., Mayer, J.M., and Gurny, R. (2002) Ocular tolerance of preservatives and alternatives. Eur. J. Pharm. Biopharm., 53, 263-280. Review. (Pubitemid 34303289)
14. Guenoun, J. M., Baudouin, C., and Rat, P. (2005) In Vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci., 46, 4594-4599 (Pubitemid 44264559)
15. Kim, M. S., Choi, C. Y., Kim, J. M., Chang, H. R., and Woo, H. Y (2008) Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br. J. Ophthalmol., 92, 1518-1521.
16. Kitazawa, Y., Smith, P., Sasaki, N., Kotake, S., Bae, K., and Iwamoto, Y. (2011) Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, double-masked comparison of safety and efficacy. Eye (Lond.), 25, 1161-1169.
17. Liang, H., Baudouin, C., Pauly, A., and Brignole-Baudouin, F. (2008) Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol., 92, 1275-1282.
18. Liang, H., Brignole-Baudouin, F., Pauly, A., Riancho, L., and Baudouin, C. (2011a) Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv. Ther., 28, 311-325.
19. Liang, H., Pauly, A., Riancho, L., Baudouin, C., and Brignole-Baudouin, F. (2011b) Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional- reconstituted corneal epithelium system. Br. J. Ophthalmol., 95, 869-875.
20. Motolko, M. A. (2008) Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr. Med. Res. Opin., 24, 2663-2667.
21. Miglior, S., Grunden, J. W., and Kwok, K., Xalacom/Cosopt European Study Group. (2010) Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye (Lond), 24, 1234-1242.
22. Pellinen, P. and Lokkila, J. (2009) Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic. Res., 41, 118-122.
23. Rahman, M. Q., Tejwani, D., Wilson, J. A., Butcher, I., and Ramaesh, K. (2006) Microbial contamination of preservative free eye drops in multiple application containers. Br. J. Ophthalmol., 90, 139-141. (Pubitemid 43163838)
24. Ryan, G. Jr, Fain, J. M., Lovelace C., and Gelotte K. M. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chlorides and travoprost with the sofZia preservative system. BMC Ophthalmol., 2011 Apr 21;11, 8.
25. Strohmaier, K., Snyder, E., DuBiner, H., and Adamsons, I. (1998) The efficacy and safety of the dorzolamide/timolol combination versus the concomitant administration of its components. Dorzolamide/Timolol Study Group. Ophthalmology, 105, 1936-1944. (Pubitemid 28509737)
26. Tasli, H., and Coşar, G. (2001) Microbial contamination of eye drops. Cent. Eur. J. Public. Health, 9, 162-164. (Pubitemid 32655941)
27. Uematsu, M., Kumagami, T., Shimoda, K., Kusano, M., Teshima, M., To, H., Kitahara, T., Kitaoka, T., and Sasaki, H. (2011) Polyoxyethylene hydrogenerated cater oil modulates benzalkonium chloride toxicity: Comparison of acute corneal barrier dysfunction induced by travoprostZ and travoprost. J. Ocul. Pharmacol. Ther., 27, 437-444
28. Uusitalo, H., Kaamiranta, K., and Ropo, A. (2008) Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta. Ophthalmol. Suppl. (Oxf.), 242, 7-13.
29. Yamaguchi, D., Ayaki, M., Yaguchi, S., Iwasawa, A., and Koide, R. (2010) Cytotoxicity of four ophthalmic solutions containing nipradilol for three corneal and one conjunctival cell lines. Folia Japonica de Ophthalmologic Clinica (in Japanese), 3, 1245-1249.